A Phase IIa, randomised, double-blind, placebo-controlled trial to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BI 706321 orally administered for 12 weeks in patients with Crohn`s Disease (CD) receiving ustekinumab induction treatment
CompletedCTIS2024-512756-38-00
Boehringer Ingelheim International GmbHCrohn`s Disease (CD)
Start: 2022-02-17End: 2024-08-08Target: 27Updated: 2024-08-05